Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on February 20, 2004; DOI: 10.1124/jpet.103.062620
0022-3565/04/3093-978-986$20.00
JPET 309:978-986, 2004
CARDIOVASCULAR
Dual Regulation of Tumor Necrosis Factor-
-Induced CCL2/Monocyte Chemoattractant Protein-1 Expression in Vascular Smooth Muscle Cells by Nuclear Factor-
B and Activator Protein-1: Modulation by Type III Phosphodiesterase Inhibition
Yung-Ming Chen,
Wen-Chih Chiang,
Shuei-Liong Lin,
Kwan-Dun Wu,
Tun-Jun Tsai, and
Bor-Shen Hsieh
Department of Medicine, National Taiwan University Hospital and College of Medicine National Taiwan University, Taipei, Taiwan
Monocyte/macrophage infiltration to the subendothelial space of arterial wall is a critical initial step in atherogenesis, in which CC chemokine ligand 2 (CCL2)/monocyte chemoattractant protein-1 (MCP-1) is thought to play a key role. This study investigated the effectiveness of phosphodiesterase inhibitors, including the nonselective pentoxifylline (PTX) and the selective type III (cilostamide) and type IV (denbufylline) inhibitors, on cytokine-induced CCL2/MCP-1 production in cultured rat vascular smooth muscle cells (VSMCs), and the signal transduction mechanisms whereby they act. Our results showed that tumor necrosis factor (TNF)-
induced a marked increase in CCL2/MCP-1 production in dose- and time-dependent manners. 2-(2-Amino-3-methoxyphenyl)-4H-1-benzopyran-4-one (PD98059), 1,4-diamino-2,3-dicyano-1,4-bis(2-aminophenylthio) butadiene (U0126) [both inhibitors of p42/44 mitogen-activated protein kinase (MAPK) kinase], and anthra[1hyphen]9-cd]pyrazol-6(2H)-one (SP600125) [an inhibitor of c-Jun NH2-terminal kinases (JNKs)] attenuated TNF-
-induced CCL2/MCP-1 production, without affecting I-
B
degradation or p65/nuclear factor-
B (NF-
B) nuclear translocation. PD98059 abolished TNF-
-activated p42/44 MAPK phosphorylation and c-Fos up-regulation, whereas SP600125 inhibited TNF-
-activated JNK and c-Jun phosphorylation. The NF-
B inhibitor carbobenzoxy-L-leucyl-L-leucyl-L-leucinal (MG132) attenuated TNF-
-induced CCL2/MCP-1 production in the presence of increased phospho-JNK and phospho-c-Jun levels. When SP600125 was added simultaneously, MG132 completely inhibited TNF-
-induced CCL2/MCP-1 production. Finally, the pretreatment of VSMCs with PTX or cilostamide, but not denbufylline, reduced TNF-
-induced CCL2/MCP-1 production, which was preceded by attenuation of p65/NF-
B nuclear translocation, p42/44 MAPK, and JNK-c-Jun phosphorylation, and c-Fos up-regulation. These data indicate that TNF-
-stimulated CCL2/MCP-1 production in rat VSMCs is dually regulated by activator protein-1 (AP-1) and NF-
B pathways, and inhibition of type III phosphodiesterase contributes substantially to the suppressive effect of PTX on CCL2/MCP-1 production via down-regulation of AP-1 and NF-
B signals.
Received November 6, 2003;
accepted February 19, 2004.
Address correspondence to: Dr. Kwan-Dun Wu, Department of Medicine, National Taiwan University Hospital, 7, Chung-Shan South Rd., Taipei, 10016, Taiwan. E-mail: kdw{at}ha.mc.ntu.edu.tw.
This article has been cited by other articles:

|
 |

|
 |
 
S. X Zhang, J. J Wang, A. Dashti, K. Wilson, M.-H. Zou, L. Szweda, J.-X. Ma, and T. J Lyons
Pigment epithelium-derived factor mitigates inflammation and oxidative stress in retinal pericytes exposed to oxidized low-density lipoprotein
J. Mol. Endocrinol.,
September 1, 2008;
41(3):
135 - 143.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Tanimoto, Y. Murata, K.-Y. Wang, M. Tsutsui, K. Kohno, and Y. Sasaguri
Monocyte Chemoattractant Protein-1 Expression Is Enhanced by Granulocyte-Macrophage Colony-stimulating Factor via Jak2-Stat5 Signaling and Inhibited by Atorvastatin in Human Monocytic U937 Cells
J. Biol. Chem.,
February 22, 2008;
283(8):
4643 - 4651.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Sakai, S. Otogoto, Y. Chiba, K. Abe, and M. Misawa
Involvement of p42/44 MAPK and RhoA protein in augmentation of ACh-induced bronchial smooth muscle contraction by TNF-{alpha} in rats
J Appl Physiol,
December 1, 2004;
97(6):
2154 - 2159.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2004 by the American Society for Pharmacology and Experimental Therapeutics.